Anthropic has introduced Claude Science, a new AI model aimed at helping researchers work faster on drug discovery, protein analysis, and other biotech tasks. The pitch is straightforward: give trusted scientists a tool that can speed up early-stage research without handing the same capability to anyone who might want to build something far uglier than a medicine.
That caution is not branding fluff. Anthropic says access should be limited to responsible, vetted companies, a sensible position in a field where the difference between useful biology and dangerous biology can be uncomfortably small. Drugmakers have already been pouring money into AI, from Nvidia compute to startup investments, because the first company to shave time off discovery usually wins the bigger prize.
Claude Science drug discovery features
For now, Claude Science is focused on the upstream part of the pipeline: generating molecular formulas, examining three-dimensional protein structures, and helping teams search for new candidate drugs. Anthropic says the model will eventually expand into clinical trials, which is where the work gets slower, more regulated, and much more expensive.
- Three-dimensional protein structure analysis
- Early-stage molecular design
- Drug discovery for ”unpopular” diseases
- Future use in clinical trials
Why Anthropic is talking about safety
Claude Science is also a reminder that AI in biotech is not just a productivity story. Dario Amodei, Anthropic’s chief executive, argues that tools like this should be distributed carefully because they could be misused for biological weapons if they fall into the wrong hands. That puts Anthropic in the same conversation as traditional biotech labs, which already work under strict safety protocols; the company seems eager to say its software should be treated with similar discipline.
There is a commercial angle too. Anthropic says the model could make it economically viable to pursue medicines for less profitable diseases that big pharma often ignores. OpenAI moved into a similar space in April with GPT-Rosalind, so the race is no longer about whether AI belongs in drug discovery. It is about which model becomes the default assistant for scientists who want to move faster without making a mess of the lab notebook.
Claude Science availability outside the US
Anthropic says Claude Science is available outside the United States through individual or enterprise subscriptions. That matters because biotech research is global, and the most interesting work rarely stays inside one country’s borders for long. The real question now is whether Anthropic keeps this as a tightly controlled specialist product, or broadens it enough to become a standard tool for drug developers before rivals do the same thing with a louder sales pitch.